Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

Inclusion Criteria:

- Clinically diagnosed by an investigator to have stable plaque psoriasis with no more
than 10% body surface area involvement.

- A subject must have an overall baseline score of 6 (moderate) or greater based on a
twelve-point scale on the Psoriasis Severity Assessment (PSA) form. Elevation,
erythema, and scale will each be graded on a four point scale with a maximum total of
12 points. Each of these 3 variables should be scored as at least a two. (Plaque
elevation is defined as the total elevation, including adherent scales, relative to
the surrounding skin).

- For female patients of childbearing potential, a regular menstrual cycle prior to
study entry (a female is considered of childbearing potential unless she is
postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal
ligation).

- Negative urine pregnancy test at the time of study entry (for female patients of
childbearing potential).

- Written, informed consent and photographic release.

- Ability to follow study instructions and likely to complete all required visits.

Exclusion Criteria:

- A female subject who is pregnant, nursing an infant or planning a pregnancy during the
study (throughout the course of the study, women of childbearing potential must use
reliable forms of contraception [i.e., abstinence, spermicides, condoms, or other
reliable forms of contraception other than oral contraceptives].

- A subject with any uncontrolled systemic disease. A potential subject in whom therapy
for a systemic disease is not yet stabilized will not be considered for entry into the
study.

- A subject with the presence of any skin disease that might interfere with the
diagnosis or evaluation of the test medications.

- A subject that has a condition or is in a situation which in the investigator's
opinion may put the patient at significant risk, may confound the study results, or
may interfere significantly with the patient's participation in the study.

- A subject with spontaneously improving or rapidly deteriorating plaque psoriasis.

- A subject with pustular or erythrodermic psoriasis.

- A subject diagnosed by an investigator to have stable plaque psoriasis involvement
that exceeds more than 10% of the subject's body surface area.

- Use of systemic agents such as oral retinoids, methotrexate, cyclosporine or systemic
corticosteroids within four weeks prior to study entry.

- Use of biologic agents such as alefacept, infliximab, efalizumab, adalimumab, or
etanercept within four weeks prior to study entry.

- Use of topical drugs that might alter the course of psoriasis (e.g., corticosteroids,
retinoids, vitamin D analogues, salicylic acid, tacrolimus, tar and anthralin,) or has
received Ultraviolet B treatment within two weeks prior to study entry.

- Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior to
study entry.

- A subject with a known sensitivity to any of the study treatments and/or their
components.

- A subject who will require excessive or prolonged exposure to ultraviolet light (e.g.,
sunlight, tanning beds) during the study.

- A subject who anticipates a need to use other topical or systemic therapy that might
alter the course of psoriasis.

- A subject who anticipates the need for surgery or hospitalization during the study.

- Concurrent involvement in any other clinical study with an investigational drug or
device, or participation in a clinical study within 30 days prior to entering the
study.